Literature DB >> 14726408

Risk of myocardial infarction and stroke in smokers is related to plasma levels of inflammation-sensitive proteins.

P Lind1, G Engström, L Stavenow, L Janzon, F Lindgärde, B Hedblad.   

Abstract

BACKGROUND: The extent to which differences in cardiovascular risk between smokers with similar daily tobacco consumption may be related to plasma levels of inflammation-sensitive proteins (ISP) and whether these proteins are associated with levels of carboxyhemoglobin (COHb%) have not been clarified. METHODS AND
RESULTS: In a population-based cohort of 1489 never smokers, 1685 former smokers, and 2901 current smokers, aged 28 to 61 years, plasma levels of orosomucoid (alpha(1)-acid glycoprotein), alpha(1)-antitrypsin, haptoglobin, fibrinogen, and ceruloplasmin were measured. COHb% levels were available for 2098 of them. Incidence of myocardial infarction, stroke, and death were monitored over 18.7+/-4.7 years. The proportion with high ISP levels (ie, > or =2 ISP in the top quartile) increased progressively with daily tobacco consumption (P<0.01) and COHb% (P<0.01). In all smoking categories, the incidence of stroke, cardiac events, and death was related to ISP. In heavy smokers, high ISP levels were associated with adjusted relative risks of 1.57 (1.05 to 2.35) and 1.50 (1.11 to 2.03) for cardiac events and death, respectively. Corresponding figures for moderate and light smokers were 1.59 (1.13 to 2.24) and 1.14 (0.87 to 1.49), respectively, and 1.32 (0.95 to 1.85) and 1.48 (1.10 to 1.98), respectively.
CONCLUSIONS: ISP levels are related to COHb% in smokers. High levels are associated with an increased cardiovascular risk.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14726408     DOI: 10.1161/01.ATV.0000116863.37311.82

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  5 in total

1.  Biomarkers of Exposure and Potential Harm in Exclusive Users of Nicotine Pouches and Current, Former, and Never Smokers: Protocol for a Cross-sectional Clinical Study.

Authors:  David Azzopardi; Linsey Ellen Haswell; Justin Frosina; Michael McEwan; Nathan Gale; Jesse Thissen; Filimon Meichanetzidis; George Hardie
Journal:  JMIR Res Protoc       Date:  2022-10-06

Review 2.  Effects of tobacco smoking and nicotine on cancer treatment.

Authors:  William P Petros; Islam R Younis; James N Ford; Scott A Weed
Journal:  Pharmacotherapy       Date:  2012-10       Impact factor: 4.705

Review 3.  Comorbidities in chronic obstructive pulmonary disease.

Authors:  Wissam M Chatila; Byron M Thomashow; Omar A Minai; Gerard J Criner; Barry J Make
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

4.  Influence of hypertension, obesity and nicotine abuse on quantitative and qualitative changes in acute-phase proteins in patients with essential hypertension.

Authors:  Maciej Cymerys; Paweł Bogdański; Danuta Pupek-Musialik; Anna Jabłecka; Jan Łącki; Izabela Korczowska; Joanna Dytfeld
Journal:  Med Sci Monit       Date:  2012-05

5.  Clinical assessment, neuroimaging and immunomarkers in Chagas disease study (CLINICS): Rationale, study design and preliminary findings.

Authors:  Jamary Oliveira-Filho; Jesângeli de S Dias; Pedro A P Jesus; Nestor J S B Neto; Roque Aras; Francisco J F B Reis; Karen L Furie
Journal:  Dement Neuropsychol       Date:  2012 Jul-Sep
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.